GlaxoSmithKline

🇬🇧United Kingdom

Country: 🇬🇧United Kingdom

Ownership: Public

Established: 1929-01-01

Employees: 70.2K

Market Cap: $90B

Website: http://www.gsk.com

Introduction: GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Clinical Trials

Efficacy and Safety Study of Sirukumab in Patients With Giant Cell Arteritis

Phase 3

Terminated

Conditions: Giant Cell Arteritis

Interventions: Drug: Sirukumab
Drug: Placebo to match sirukumab
Drug: Prednisone
Drug: Placebo to match prednisone

First Posted Date: 2015-08-24

Last Posted Date: 2019-07-31

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 161

Registration Number: NCT02531633

Locations: 🇬🇧
GSK Investigational Site, Reading, United Kingdom

GSK3174998 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors (ENGAGE-1)

Phase 1

Completed

Conditions: Neoplasms

Interventions: Drug: GSK3174998
Drug: Pembrolizumab

First Posted Date: 2015-08-19

Last Posted Date: 2021-05-18

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 141

Registration Number: NCT02528357

Locations: 🇳🇱
GSK Investigational Site, Amsterdam, Netherlands

A Study to Evaluate the Safety, Efficacy and Changes in Induced Sputum and Blood Biomarkers Following Daily Repeat Doses of Inhaled GSK2269557 in Chronic Obstructive Pulmonary Disease (COPD) Subjects With Acute Exacerbation

Phase 2

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

Interventions: Drug: GSK2269557
Drug: Placebo
Device: ELLIPTA
Device: DISKUS

First Posted Date: 2015-08-13

Last Posted Date: 2021-09-05

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 44

Registration Number: NCT02522299

Locations: 🇩🇰
GSK Investigational Site, Odense, Denmark

New Method Using Deuterium Labelled Creatine to Measure Total Body Skeletal Muscle Mass

Not Applicable

Completed

Conditions: Sports Nutritional Sciences

Interventions: Dietary Supplement: D3 Creatine
Dietary Supplement: Creatine

First Posted Date: 2015-08-11

Last Posted Date: 2015-08-11

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 20

Registration Number: NCT02519751

Locations: 🇬🇧
GSK Investigational Site, Brentford, United Kingdom

Pharmacokinetics, Safety and Tolerability of Repeat Dosing Lamotrigine in Healthy Chinese Subjects

Phase 1

Completed

Conditions: Bipolar Disorder

Interventions: Drug: Lamotrigine

First Posted Date: 2015-07-31

Last Posted Date: 2017-05-08

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 16

Registration Number: NCT02513654

Locations: 🇨🇳
GSK Investigational Site, Shanghai, China

Bioavailability Study of Fixed Dose Combination (FDC) Dutasteride and Tamsulosin Hydrochloride (HCl) Relative to One Dutasteride and One Tamsulosin HCl Tablet in Healthy Male Subjects

Phase 1

Completed

Conditions: Prostatic Hyperplasia

Interventions: Drug: FDC capsule of dutasteride and tamsulosin
Drug: Dutasteride soft gelatine capsule and tamsulosin HCl oral disintegrating tablet

First Posted Date: 2015-07-27

Last Posted Date: 2018-06-19

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 56

Registration Number: NCT02509104

Locations: 🇺🇸
GSK Investigational Site, Baltimore, Maryland, United States

Study to Evaluate the Efficacy and Safety of GSK3196165 Plus Methotrexate in Subjects With Active Moderate-Severe Rheumatoid Arthritis

Phase 2

Completed

Conditions: Arthritis, Rheumatoid

Interventions: Drug: GSK3196165
Drug: MTX
Drug: Folic acid
Drug: Placebo

First Posted Date: 2015-07-22

Last Posted Date: 2021-01-11

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 222

Registration Number: NCT02504671

Locations: 🇬🇧
GSK Investigational Site, Leeds, United Kingdom

Bioequivalence Study for Mejoral 500 Product

Not Applicable

Completed

Conditions: Pain

Interventions: Drug: Mejoral® 500 Tablets
Drug: Tylenol® Caplets

First Posted Date: 2015-07-22

Last Posted Date: 2018-07-19

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 28

Registration Number: NCT02504775

Locations: 🇲🇽
GSK Investigational Site, Mexico City, Mexico

Bioequivalence Study of Clopidogrel 75 mg in Two Tablet Formulations Relative to Reference Tablet in Healthy Subjects

Phase 1

Completed

Conditions: Cardiovascular Disease

Interventions: Drug: Clop F1
Drug: Clop F2
Drug: Innovator

First Posted Date: 2015-07-20

Last Posted Date: 2017-05-08

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 18

Registration Number: NCT02502812

Locations: 🇮🇳
GSK Investigational Site, Telangana, India

Effect of Inhaled Fluticasone Furoate on Short-term Growth in Paediatric Subjects With Asthma

Phase 3

Completed

Conditions: Asthma

Interventions: Drug: Fluticasone furoate
Drug: Placebo
Drug: Salbutamol

First Posted Date: 2015-07-20

Last Posted Date: 2017-11-17

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 60

Registration Number: NCT02502734

Locations: 🇩🇰
GSK Investigational Site, Randers, Denmark

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy